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Abstract
Background: Attitudes towards antipsychotic medication play an important part in the treatment
for schizophrenia and related disorders. We aimed measuring general practitioners' attitudes to
antipsychotic drugs and their adverse side effects and comparing these with the attitudes of the
general population.
Methods: Analysis and comparison of two representative samples, one comprising 100 General
Practitioners (GPs), the other 791 individuals randomly selected from the general population. The
setting was the German speaking cantons of Switzerland.
Results: General practitioners have significantly more positive attitudes towards anti-psychotic
drugs than the general public. They reject widespread prejudices about the use of anti-psychotic
medication significantly more than the general population. In particular the risk of dependency was
assessed as 'low' by GP's (80%), in contrast to only 18% of the general population sample. In no
instance did a majority of the GPs advise not tolerating any of the 10 possible adverse effects
presented in this study. This is in marked contrast to the general population sample, where a
majority recommended discontinuation for movement disorder (63%), strong tremor (59%), risk
of dependency (55%) and feelings of unrest (54%).
Conclusion: As well as effective management of side-effects being a vital aspect of patient and
carer education, prescribing doctors need to be aware that their mentally ill patients are likely to
be confronted with extremely negative public attitudes towards antipsychotic medication and with
strong pressures to stop taking their medication in the event of side-effects.
Background
Attitudes towards antipsychotic medication play an
important part in the treatment for schizophrenia and
related disorders. The effectiveness of antipsychotic medi-
cation is evident in acute and maintenance treatment of
these disorders, and most mental health professionals rec-
ognize antipsychotic drugs as a cornerstone in treating
affected people [1]. The general public, on the other hand,
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are often sceptical and negative in their attitudes to anti-
psychotic drugs. They believe the risks of such drugs out-
weigh the possible benefits [2], and they are negatively
stereotyped as being only "symptom alleviating", only
"masking the actual problems"[3]. Negative attitudes of
people with mental illness towards antipsychotic treat-
ment are known to have a negative impact on their treat-
ment adherence [4-6].
Side effects of antipsychotic drugs such as extrapyramidal
symptoms contribute to their poor public perception [3],
and there is extensive evidence that distress from side
effects is an important contribution to noncompliance
[7]. Tolerance of adverse side effects by patients is influ-
enced, among others, by a good doctor patient relation-
ship [8,9], the attitudes of prescribing doctors, and their
ability to explain the proposed treatment in an under-
standable way and to address patients' concerns [10].
Most General Practitioners (GPs) give medical care to psy-
chotic patients. GPs ought to know the attitudes of these
patients and should able to make allowances for the diver-
gent perspectives. The goal of this study was to assess GPs
attitudes towards anti-psychotic medications and their
adverse side effects, and to what extent medical and public
opinion on these subjects diverge.
Methods
This study design compared attitudes towards antipsy-
chotic drugs and their side effects of general practitioners'
and the general public using computer assisted telephone
(CATI) interviews.
Samples
GPs
A letter outlining the study was sent to 190 general practi-
tioners, selected at random from all GPs in the German
speaking part of Switzerland in 2000. The sample was
stratified by gender (50%:50%) in order to achieve com-
parability with the general population sample which had
been investigated in a preliminary study [11]. One week
after the letter, attempts were made to reach all 190 GPs
by telephone. 23 could not be reached having moved,
given up their practices, or were long term absent. Of the
remaining 167, 100 agreed to participate, resulting in a
response rate of 59.8%.
General population
The lay sample was derived from a public opinion survey
on attitudes towards the mentally ill carried out in 1999.
It is a representative sample of the Swiss residential popu-
lation aged 16 to 76 years (N = 1737). Details about the
public opinion survey have been published elsewhere
[11,12]. In this analysis, only the interviews from the Ger-
man speaking part of Switzerland (N = 791) were used.
The methodology of the public opinion survey (CATI,
questions about antipsychotic medication and tolerance
of side effects) was replicated in the present study.
Variables examined
Firstly, general attitudes towards anti-psychotic drugs
were assessed by asking for agreement or disagreement
with 7 statements [2] about their effectiveness, benefits
and risks and about some widespread prejudices against
them (specific questions see table 1). The interviewees
were asked to rate each statement on a five point scale
from 1 "completely correct" to 5 "completely wrong".
Secondly, a vignette describing a person who met the
DSM-III-R diagnostic criteria for schizophrenia was pre-
sented to all interviewees in the GP's sample and to 398
out of the 791 general population sample. Subjects were
asked how long the person depicted should be willing to
tolerate some side effects of medication (mouth dryness,
sweating, tiredness, sexual dysfunction, feeling of unrest,
weight gain, visible movement disorders, anhedonia, risk
of drug addiction, tremor). The answers were represented
by three response categories (never, up to 2–3 weeks, for
longer periods). For more details about the questionnaire,
see Lauber et al. [12].
Data analysis
The Mann-Whitney U-test was used to detect differences
between the two samples. We performed no correction for
multiple testing. The data were computed using the com-
puter package SPSS, Version 9.0 for Windows.
Results
General attitudes towards antipsychotic medication
GPs reported generally very positive attitudes towards
antipsychotic drugs. A vast majority (86%) thought that
the benefits of antipsychotic drug treatment far outweigh
the risk associated with it.
All GP's agreed with the assertion that the duration of stay
in psychiatric hospitals has shortened since the introduc-
tion of antipsychotic drugs, and 79% state, that people
with mental illness can only be supported by their rela-
tives due to these treatments. However only 56% agreed
with the assertion that antipsychotic drug treatment is the
most effective way to treat psychotic illness.
All comparisons between GPs' and the general popula-
tion's assessments show significant differences, most
noticeably on whether antipsychotic drug treatment car-
ries a high risk of dependency. Here 80% of the GPs
assessed the risk as low but only 18% of the general pop-
ulation shared this opinion. Also, generalised prejudices
against the medication were judged incorrect by the vast
majority of general practitioners, whereas only a minorityBMC Psychiatry 2006, 6:42 http://www.biomedcentral.com/1471-244X/6/42
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of the general population sample rejected them (Drugs
can only calm down patients 88% vs. 35%, and make
them even more ill 92% vs. 45%. For complete results see
Table 1). On questions about the usefulness of anti-psy-
chotic medication treatment (1, 3, 6 and 7), doctors
assessed positive aspects significantly higher.
Tolerance of side effects
GPs show themselves to be more ambivalent on questions
about how long certain antipsychotic drug side effects of
should be tolerated (see Table 2). Long-term tolerance
was advised despite dry-mouth (83%), heavy sweating
(59%), significant weight gain (50%) and risk of drug
dependency (68%). In eight out of 10 side effects, more
than one third of the general practitioners opted to con-
tinue treatment for a further two to three weeks. Advice
not to tolerate a side effect at all was never given by a
majority of the GPs.
This is in marked contrast to the general population sam-
ple. Here a majority voted not to tolerate treatment in the
presence of movement disorder (63%), marked tremor
(59%), risk of dependency (55%) and feeling of unrest
(54%). GPs voted significantly more often for long-term
tolerance than did the general population concerning the
occurrence of all side effects with the exception of 'contin-
uous feeling of unrest'. In spite of these differences, gen-
eral practitioners and the public show some similar
patterns: Both groups were least accepting of apparent
movement disorders, continuing feeling of unrest,
marked tremor and persisting anhedonia. Accordingly,
the Spearman's r for "no tolerance" of side effects was .88
(p < .001) between GPs and the general population.
Discussion
The attitudes of mental health professionals and those of
the public towards antipsychotic medication may be
assumed to diverge. In addition to any personal reserva-
tions they may have about their treatment patients taking
antipsychotic drugs are under pressure from public atti-
tudes to doubt their benefits and efficacy. It is crucial for
successful therapy that patients are well-informed by the
prescribing physician and that they are also given compre-
hensive and appropriate information. Traditionally this is
assumed to come from psychiatrists but Kendrick et al.
[13] showed that long-term psychotic patients have fre-
quent contact with their GPs and are influenced by their
opinions. This study investigated the attitudes of general
practitioners towards antipsychotic medication and com-
pared them with the attitudes of the public.
Principal findings
General practitioners have significantly more positive atti-
tudes towards the use of anti-psychotic drugs and opin-
ions of their effectiveness than do the general public. They
reject widespread prejudice about the use of such drugs
significantly more strongly than the general public. It is
highly likely that they will advise their patients to tolerate
possible adverse side effects of these medications longer
than lay persons do. There is no published literature on
Table 1: Percentage distribution of GP's (N = 100) and public attitudes (N = 791) towards statements about antipsychotic medication
General Practitioners lay persons P
disagree rather
disagree
undecided rather
agree
agree disagree rather
disagree
undecided rather
agree
agree
1. Antipsychotic drug treatment is the 
most effective way to treat mental 
illness
7.1 4 33.3 29.3 26.3 9 17.7 37.1 26.5 9.7 ***
2. Antipsychotic drug treatment 
carries a high risk of dependency
45 35 12 3 5 3.7 14 27.8 33.6 20.9 ***
3. The benefits of antipsychotic drug 
treatment far outweighs the risk 
associated with it
1 0 13 36 50 2.9 12 40.1 32.9 12.1 ***
4. Treatment with antipsychotic drugs 
can only calm patients down
68.7 19.2 6 5.1 1 15.2 20 28.2 24.8 11.7 ***
5. In the long run antipsychotic drugs 
make one even more ill than before
69 23 7 0 1 15 29.7 29.3 17.2 8.8 ***
6. Mentally ill people are only tolerable 
for their relatives due to antipsychotic 
drug treatment
3 1 17.2 40.4 38.4 2.4 9 29.3 42.8 16.5 ***
7. Since the introduction of 
antipsychotic drugs, the duration of 
stay in psychiatric hospitals has 
become much shorter
0 0 0 24.2 75.8 2.6 9.9 22.7 45.6 19.2 ***
*** = p < 0.001 approximate significance levelBMC Psychiatry 2006, 6:42 http://www.biomedcentral.com/1471-244X/6/42
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the attitudes of psychiatrists in this area so it is difficult to
know if patients are exposed to differing professional
opinions.
This study showed that the general population and the
GPs have contrary ideas on the risk of drug dependency
and whether or not drug dependency should be tolerated,
with 80% of the GPs not agreeing that antipsychotics have
a risk of dependency whereas the majority of the general
population does. The two groups have comparable opin-
ions on how long patients should accept visible move-
ment disorders. Moreover, they both believe that the
duration of inpatient stay has become much shorter since
the introduction of antipsychotics, but reject the belief
that people with mental illness are only tolerable for their
relatives due to antipsychotic drug treatment.
Strengths and weaknesses of the study
This is the first study to assess GPs' attitudes towards
antipsychotic drugs, and to compare these results with
attitudes in a representative sample of the general popula-
tion. There is likely to be a degree of bias in our findings
as our subjects are likely to be drawn from amongst the
more communicative and cooperative members of these
populations., Respondents' answers could also be biased
by social desirability. However we attempted to minimise
this influence by choosing telephone interviews, which
are generally considered superior to face-to-face inter-
views in terms of confidentiality and social desirability.
[14].
Implications for clinicians and policymakers
Patients often doubt the benefits and the efficacy of antip-
sychotic drugs. They are also less tolerant of adverse side
effects than their GPs would consider acceptable for the
therapeutic benefits. GPs and the public differ very much
in their opinions as to how long side effects should be tol-
erated. The ability to anticipate, manage and tolerate these
side effects is a vital component of patient and carer edu-
cation [8]. Prescribing doctors need also to recognise that
their mentally ill patients will be exposed to extremely
negative public attitudes towards antipsychotic medica-
tion. This will often be accompanied by advice to stop
them in the event of side effects. Patients report a general
lack of information on the reasons for prescribing anti-
psychotics and on the side effects that may accompany
them [15,16]. Being better informed, particularly about
side effects, should strengthen their resistance to ill-
informed public opinion and prejudice.
New developments in psychiatric care such as "shared
decision making" [17,18] and an improved assessment
and management of side effects [19] need to be more
effectively communicated to the public, to improve gen-
eral understanding and, consequently, attitudes to their
use. There is a pressing need for public awareness pro-
grammes to raise understanding in this area.
The GPs' attitudes uncovered in this study also call for
action. Their willingness to tolerate side effects for two to
three weeks and their certain lack of understanding that
antipsychotic drugs do not create dependency underline
the need to develop education programmes specifically
aimed at general practitioners about the rapidly develop-
ing field of antipsychotic medication.
Conclusion
In the context of mental disorders, the premisses regard-
ing the use of antipsychotic drugs differ broadly. Prescrib-
ing doctors need to be aware that their mentally ill
patients are likely to be confronted with extremely nega-
tive public attitudes towards antipsychotic medication.
Doctors should anticipate the most relevant prejudices
and address them explicitely.
Table 2: Percentage distribution of GPs' (N = 100) and lay people's opinions (N = 398) as to how long the side effects of antipsychotic 
drugs should be tolerated
General Practitioners lay persons P
No tolerance 2–3 weeks Long-term No tolerance 2–3 weeks Long-term
Unpleasant dry mouth 2 15.2 82.8 18.3 49.5 32.2 ***
Heavy sweating 3 38.4 58.6 26.1 50.1 23.8 ***
Continuous tiredness 5.1 54.5 40.4 24.4 56.9 18.7 ***
Frequent sexual dysfunction 4.1 52.6 43.3 27.1 51 21.9 ***
Continuous feeling of unrest 43.4 45.5 11.1 53.5 38.3 8.2 n.s.
Significant weight gain 9.3 41.2 49.5 35.9 46.4 17.7 ***
Visible movement disorder 48.5 40.4 11.1 62.8 27.8 9.4 *
Continuous anhedonia 24.5 60.2 15.3 33.9 55.4 10.7 *
Risk of drug dependency 22.7 9.1 68.2 55.2 30.1 14.7 ***
Marked tremor 33.7 54.1 12.2 58.9 33.7 7.4 ***
*** = p < 0.001 * = p < 0.05 approximate significance levelPublish with BioMed Central    and   every 
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